MET and non-small cell lung carcinoma: This was based on data from a multicenter, multicohort phase 2 study evaluating the efficacy and safety of savolinitib in unresectable or metastatic NSCLC with MET exon 14 altered NSCLC or metastatic pulmonary sarcomatoid carcinoma (PSC) in Chinese patients [85].